|
April-2003
|
Diagnosed with stage II breast cancer
|
Surgery and adjuvant chemotherapy (adriamysin/cytoxan, and weekly docataxel)
|
na
|
|
March-2007
|
Developed liver, lungs, lymph nodes, and skeletal metastases
|
Chemotherapy (gemcitabine/docetaxel with concurrent IV trastuzumab/zoledronic acid), resulted in clinical remission
|
na
|
|
April-2010
|
Loss of hearing and left facial with recurrence in left internal auditory canal and LM
|
Cyberknife therapy for IAC tumors and chemotherapy (lapatinib/capecitabine), resulted in significant improvement in neurological symptoms and imaging
|
na
|
|
October-2010
|
Ommaya inserted
|
Experimental IT trastuzumab (5 mg flat dose per week)
|
12.3
|
|
January-2011
|
New parenchymal, thoracic and lumbar LM metastases with additional 5th cerebral nerve and c1 lesions
|
Whole brain and spine radiation and increased IT trastuzumab (10 mg per week)
|
12.6
|
|
July-2011
|
Worsening intramedullary c1 lesions
|
One month of IT trastuzumab (50–80 mg per week) and maximal dose of cyber knife therapy
|
32.8
|
|
March-2013
|
Developed weakness in left hip/leg and enhancement in previously stable thoracic and lumbar lesions
|
Increased total dose of IT trastuzumab (50–80 mg BIW, dose divided twice per week) administered by lumbar puncture and ommaya reservoir injections
|
40
|
|
May-2013
|
No discernable change in disease progression
|
Trastuzumab (administered bimonthly for maintenance at 50 % of the weekly dose) and lapatinib (750 mg, BID five days weekly), resulted in decreased enhancement and activity of thoracic and lumbar lesions
|
59
|
|
June-2013
|
Diagnosed with meningitis
|
Extended antibiotic treatment for two plus months (vancomycin)
|
58
|
|
July-2013
|
Hiatus from IT with an increase in CA27.29
|
T-DM1
|
37
|
|
August-2013
|
Removed ommaya
| |
50
|
|
September-2013
|
New ommaya inserted
|
Restarted IT trastuzumab (40 mg per week)
|
50
|
|
October-2013
|
Worsening neurological symptoms
|
IT trastuzumab 50 mg (100 mg per week)
|
40
|
|
August-2014
|
Patient expired
| |
40
|
